Healthcare
Camp4 Therapeutics Corp.(CAMP)
Live Price
Offline$3.88
-3.72% today
1Y Change
+172.37%
Window
Jun 27, 2025 โ Jun 17, 2026
- Market Cap
- $80.00M
- Revenue Growth
- +436.5%
- EPS Growth
- +0.4%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 27, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Camp4 Therapeutics Corp. (CAMP) is a Healthcare stock with a market cap of $80.00M and listed on NASDAQ. The stock last traded around $3.88 and up 172.4% across the available one-year price window (Jun 27, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +436.5%, EPS growth of +0.4%, a dividend yield of 0.0%. What stands out right now is revenue +436.5%, EPS +0.4%, free cash flow +35.2% with operating margin -1488.3% and ROIC -50.8%. Valuation already assumes a fairly strong business story at price/sales 24.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines CAMP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+436.5% vs +7.6% peer median
Operating Margin
Below sector median
-1488.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +436.5% and EPS at +0.4%, with operating margin around -1488.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.0% | -7.8% | -3.6% |
2026 Mar 5, 2026 | -180.7% | -8.5% | +17.2% | -2.6% |
2025 Nov 6, 2025 | -17.0% | -4.5% | -4.0% | -27.0% |
Benchmark Edge
CAMP vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CAMP
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CAMP Max Drawdown
-51.75%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CAMP and SPY.
Company Overview
Camp4 Therapeutics Corp.
NASDAQ
Camp4 Therapeutics Corp. is a biotechnology company focused on developing innovative therapeutics by unlocking the potential of gene regulation. The company's core mission is to harness the knowledge of transcriptional machinery and regulatory RNA maps, pioneering in the precision medicine landscape. Camp4 Therapeutics targets a wide array of conditions, primarily genetically driven diseases, by delicately manipulating gene expression to restore normal cellular function. The firm's approach uniquely positions it to impact the broader healthcare and pharmaceutical industries significantly. By translating cutting-edge genomic insights into actionable therapeutic strategies, Camp4 aims to address unmet medical needs and enhance patient outcomes. The company's progress and pipeline developments are closely watched by stakeholders, reflecting its potential to contribute meaningfully to the biotech sector and ultimately, patient care.
- Leadership
- Mr. Joshua Mandel-Brehm
- Employees
- 48
- Street Address
- One Kendall Square, 3rd Floor Building 1400 West
- Mailing
- Cambridge, MA, 02139
- Region
- Cambridge, MA, United States
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.4
- Price/Sales
- 24.2
- Price/Book
- 4.3
Growth
- Revenue
- +436.5%
- EPS
- +0.4%
- Free Cash Flow
- +35.2%
Profitability
- Gross Margin
- 77.5%
- Operating Margin
- -1488.3%
- Net Margin
- -2298.5%
- ROE
- -162.5%
- ROIC
- -50.8%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 7.35
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.